FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis

Save

On Friday October 21st the U.S. Food and Drug Administration approved upadacitinib (Rinvoq) for the treatment of active non-radiographic axial spondyloarthritis in patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor blocker therapy.

ACR Award Winners (10.21.2022)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

Vaccination Cut Long COVID Risk for Rheum Patients

Save

Patients with rheumatologic conditions who developed breakthrough COVID-19 infection after vaccination were less likely to suffer long-term symptoms than unvaccinated but otherwise similar patients, researchers said.

Pregnancy Outcomes with Belimumab

Save

Pregnancy in systemic lupus erythematosus (SLE) is fraught with problems of adverse pregnancy outcomes, more pregnancy loss and birth defects. Now a study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects.

Prevotella Immune Response in Both Pre-Clinical & Established RA

Save

In a recent analysis published in Arthritis & Rheumatology, people at risk for rheumatoid arthritis (RA) and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc). 

Miners Face Increased Risk of Rheumatoid Arthritis

Save

Add "hard rock" mining to the list of occupations associated with high rates of rheumatoid arthritis (RA), a new study indicated, with silica exposure the presumed malefactor.

CRTAC1- a Novel Biomarker for Osteoarthritis

Save

Scientists at deCODE genetics a subsidiary of Amgen report in Arthritis & Rheumatology that a novel plasma protein (cartilage acidic protein-1; CRTAC1) is a potential biomarker of osteoarthritis (OA) through its association with OA risk and progression to joint replacement.

Primer on Clinical Trials

Save

In this week's special podcast, Dr. Jack Cush offers a primer on rheumatology clinical trials, answering the question: should you be involved in research and clinical trials in rheumatology?

Predicting Cardiovascular Events in SLE

Save

A study from the Georgia Lupus Registry shows that systemic lupus erythematosus patients are at greatest risk for cardiovascular disease events between years 2 and 11 after diagnosis and higher in Black people or those with a discoid rash.

Second Efforts in Treating RA Partial Responders

Save

The results of a treat-to-target (T2T) combination therapy trial in patients with early rheumatoid arthritis (RA) show that if patients fail to respond initially, then a second, more intensified regimen can turn initial nonresponders into responders.

ACR Announces 2022 Award Recipients

Save

The American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP) proudly recognizes the recipients of its 2022 Master of the ACR and ARP designations, ACR Awards of Distinction, and ARP Awards of Merit and Appreciation.

Good Outcomes with TNF Blocker Use During RA Pregnancies

Save

A prospective cohort study of treatment and pregnancy outcomes in women with RA shows that TNF inhibitor use during pregnancy did not increase the risk of adverse pregnancy outcomes, but instead led to more positive outcomes such as fewer low-birth-weight deliveries.